Cancer Family
Mast Cell Neoplasm
CI-CAN-00000257Explore in graph →
HematologicNon-malignant9 active trials2 approved drugs4 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000257Explore in graph →
Clinical trials
101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05609942 | Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies(AZURE) | terminated | Phase 1 | 9 | Blueprint Medicines CorporationINDUSTRY | 7 | Apr 10, 2025 | clinicaltrials |
| NCT03214666 | GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies | terminated | Phase 1 / Phase 2 | 12 | GT Biopharma, Inc.INDUSTRY | 1 | Nov 10, 2022 |
| clinicaltrials |
Data updated 23 days agoSource updated Apr 10, 2025source: clinicaltrials